Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

CTO: Trials vs. Real-World

Percutaneous coronary intervention of chronic total occlusions (CTO) is currently indicated for symptom improvement, as studies have inadequate randomization of data which hinders the assessment of hard outcomes. However, patient inclusion in randomized controlled trials has been challenging, especially for highly symptomatic and higher risk patients. This causes a selection bias in randomized studies on CTOs.

CTO: Trials vs Mundo Real

The purpose of this meta-analysis was to evaluate the differences between patients with CTOs in the real world vs. those who were included in randomized studies.

Outcomes were evaluated in terms of procedural success, in-hospital mortality, acute myocardial infarction (AMI), major cardiovascular events (MACE), and cardiac tamponade. Procedural success was defined as technical success (<30% residual stenosis with TIMI 3 flow) without MACE.

In this study, the analysis included 6 randomized controlled studies comparing CTA to CTO vs. medical treatment (N = 1047), 10 CTO-dedicated registries (N = 76,467), and 5 national registries (N = 110,349). Most patients in the randomized studies were men and had a trend of lower comorbidities such as diabetes, hypertension, peripheral artery disease, prior AMI, prior CTA, and prior myocardial revascularization surgery. In addition, these patients underwent procedures with longer fluoroscopy time and greater use of contrast material.

Procedural success was significantly lower in the national registries compared with the randomized studies (63.9% vs. 84.5%, relative difference = 24.4%). However, randomized studies had a higher risk of in-hospital events, including death (1.3% vs. 0.6%, relative difference = 52.3%), MACE (7.9% vs. 1.5%, relative difference = 81.0%), AMI (5.9% vs. 1.0%, relative difference = 83.1%), and cardiac tamponade (0.9% vs. 0.3%, relative difference = 66.7%).

Read also: Longitudinal Deformation of a Stent with the POT Technique.

When comparing patients from randomized studies vs. CTO-dedicated registries, patients included in the studies had shorter CTOs and low J-CTO scores (2.0-1.1 vs. 2.3-1.2, relative difference = 13.0%). Although procedural success was similar between both groups (84.5% vs. 81.4%), patients included in the studies presented a higher risk of in-hospital events (death, MACE, AMI, and cardiac tamponade).

Conclusion

Patients included in the randomized studies had less risk profile and less injury complexity than real-world registries. Current evidence from randomized controlled studies may not be representative of real-world patients and should be interpreted with this limitation. Procedures performed by surgeons specialized in CTOs have significantly more success and fewer complications than those performed by surgeons that are not specialized in CTOs.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Comparative Analysis of Patient Characteristics in Chronic Total Occlusion Revascularization Studies Trials vs Real-World Registries.

Reference: Michael Megaly, MD  et al J Am Coll Cardiol Intv 2022;15:1441–1449.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...